beta
Trial Radar AI

Showing clinical trials matching location: France.

I can help you find clinical trials in specific locations and provide insights on health conditions and treatments.

With advanced mode, access powerful pre-screening tools, interactive data visualizations, customized email alerts for trial updates and more.

18 Results
 
Status (Default)
Not yet Recruiting, Recruiting, Active, Not Recruiting
×
 
Keywords
Metastatic Castration-resistant Prostate Cancer, Neoplasms
×
 
Location
France
×
 
Biological Sex
All
×
 
Phase
Phase 1
×
 
Type
Drug, Device
×
 
Study Title
Status
Conditions
Other IDs
Lead Sponsor
Collaborators
Sites
Phase
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) NCT06353386
Recruiting
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer NCT06190899
Recruiting
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer NCT07189403
Recruiting
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) NCT06863272
Recruiting
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer NCT04577833
Active, not recruiting
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (CYPIDES) NCT03436485
Active, not recruiting
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) NCT02861573
Recruiting
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer NCT04898634
Recruiting
A Study of GSK5764227 in Participants With Advanced Solid Tumors NCT06551142
Recruiting
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer NCT06318273
Recruiting